3 Secret Strategies to Nabbing Your Dream Home
Sonic Decanter Makes Cheap Wine Taste Expensive
Restaurant's Decadent Thanksgiving Feast: $35,000 for 4
The 5 Worst Investments of 2014
Is Celgene the Perfect Stock?
Biotechnology company Celgene (CELG) announced it is buying Abraxis BioScience (ABII) for $2.9 billion in cash and stock. With this acquisition, Ceglene is expanding its portfolio of cancer treatments.